Suchergebnisse - "Kazandjian, Dickran"

PubPharm (95)

21

Current perspectives, guiding lights to the future, and transforming care for patients with multiple myeloma

enthalten in: Seminars in oncology | 2022

von Kazandjian, D.

22

Daratumumab : A review of current indications and future directions

enthalten in: Seminars in oncology | 2022

von Hill, E. | Morrison, C. | Kazandjian, D.

23

Current and prospective antibody-based therapies in multiple myeloma

enthalten in: Seminars in oncology | 2022

von Bryer, E. | DeStefano, C. | Kazandjian, D.

24

The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S

enthalten in: Seminars in oncology | 2022

von Peres, L. | Hansen, D. | Maura, F. | +1

25

Monoclonal gammopathies of clinical significance (MGCS) : In pursuit of optimal treatment

enthalten in: Frontiers in immunology | 2022

von Oganesyan, A. | Gregory, A. | Malard, F. | +5

26

Diagnosed with myeloma before age 40

enthalten in: Blood | 2021

von Landgren, O. | Kazandjian, D.

CommentOn: Blood. 2021 Dec 23;138(25):2686-2695. - PMID 34479366

27

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma : A Phase 2 Nonrandomized Controlled Trial

enthalten in: JAMA oncology | 2021

von Kazandjian, D. | Hill, E. | Dew, A. | +31

28

Minimal Residual Disease in Myeloma : Application for Clinical Care and New Drug Registration

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Anderson, K. | Auclair, D. | Adam, S. | +47

29

A new era of novel immunotherapies for multiple myeloma

enthalten in: Lancet (London, England) | 2021

von Kazandjian, D. | Landgren, O.

30

The mutagenic impact of melphalan in multiple myeloma

enthalten in: Leukemia | 2021

von Maura, F. | Weinhold, N. | Diamond, B. | +4